Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
5
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Vascular Dementia
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Rivastigmine 1 A Pharma
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
View on EMARivastigmine Hexal
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
View on EMARivastigmine Sandoz
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
View on EMAPrometax
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
View on EMAExelon
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.
View on EMAInfluenza
Heart Transplantation
Non-alcoholic Fatty Liver Disease (NAFLD)
Meningococcal Meningitis
Axial Spondyloarthritis